(Q38164537)

30 August 2017

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? (English)

1 reference

30 August 2017

0 references

Richard E Gilbert

1

1 reference

PubMed ID

24257692

30 August 2017

language of work or name

English

0 references

publication date

20 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

86

1 reference

30 August 2017

4

1 reference

30 August 2017

693-700

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2013.451

30 August 2017

0 references

cites work

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Hemodynamically mediated glomerular injury and the progressive nature of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

A role for uric acid in the progression of renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Uric acid and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Serum uric acid as a new player in the development of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of tranilast in early-stage diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Tranilast slows the progression of advanced diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

New and emerging therapies for gout

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Serum urate, serum glucose and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Serum uric acid, serum glucose and diabetes: relationships in a population study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of phloridzin on uric acid excretion in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renal transport of uric acid: evolving concepts and uncertainties

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Solute carrier family 2, member 9 and uric acid homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Type 2 diabetes mellitus management in Canada: is it improving?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renal expression of transforming growth factor-β inducible gene-h3 (βig-h3) in normal and diabetic rats11See Editorial by Border and Noble, p. 1390

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2013.451

7 January 2021

Identifiers

DOI

10.1038/KI.2013.451

1 reference

PubMed ID

24257692

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24257692